Sotagliflozin reduces adverse cardiovascular events
- PMID: 33235374
- DOI: 10.1038/s41569-020-00486-0
Sotagliflozin reduces adverse cardiovascular events
Comment on
-
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
-
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200892 Clinical Trial.
References
Original articles
-
- Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2030186 (2020) - DOI - PubMed
-
- Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2030183 (2020) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources